{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:45:58Z","timestamp":1782179158112,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01114-2","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:05:40Z","timestamp":1772510740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a population pharmacokinetic model for lacosamide in adult patients with epilepsy to inform precision dosing"],"prefix":"10.1186","volume":"27","author":[{"given":"Lingyan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangzhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"1114_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","volume":"88","author":"KM Fiest","year":"2017","unstructured":"Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88:296\u2013303. https:\/\/doi.org\/10.1212\/WNL.0000000000003509.","journal-title":"Neurology"},{"key":"1114_CR2","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure Medications for Adults With Epilepsy: A Review. JAMA. 2022;327:1269\u201381. https:\/\/doi.org\/10.1001\/jama.2022.3880.","journal-title":"JAMA"},{"key":"1114_CR3","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2174\/1570159X21666230616114255","volume":"21","author":"Y-S Chen","year":"2023","unstructured":"Chen Y-S, Lai M-C, Chen T-S, Tseng Y-H, Li YJ, Huang C-W. Effectiveness and Safety of Lacosamide, A Third-generation Anti-seizure Medication, for Poststroke Seizure and Epilepsy: A Literature Review. Curr Neuropharmacol. 2023;21:2126\u201333. https:\/\/doi.org\/10.2174\/1570159X21666230616114255.","journal-title":"Curr Neuropharmacol"},{"key":"1114_CR4","doi-asserted-by":"publisher","first-page":"CD008841","DOI":"10.1002\/14651858.CD008841.pub3","volume":"5","author":"RK Babar","year":"2021","unstructured":"Babar RK, Bresnahan R, Gillespie CS, Michael BD. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2021;5:CD008841. https:\/\/doi.org\/10.1002\/14651858.CD008841.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1114_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","volume":"54","author":"W Cawello","year":"2015","unstructured":"Cawello W. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide. Clin Pharmacokinet. 2015;54:901\u201314. https:\/\/doi.org\/10.1007\/s40262-015-0276-0.","journal-title":"Clin Pharmacokinet"},{"key":"1114_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000339077","volume":"90","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R, Boekens H. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide. Pharmacology. 2012;90:40\u20136. https:\/\/doi.org\/10.1159\/000339077.","journal-title":"Pharmacology"},{"key":"1114_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/17425255.2017.1360278","volume":"13","author":"S de Biase","year":"2017","unstructured":"de Biase S, Valente M, Gigli GL, Merlino G. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opin Drug Metab Toxicol. 2017;13:997\u20131005. https:\/\/doi.org\/10.1080\/17425255.2017.1360278.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1114_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","volume":"37","author":"W Cawello","year":"2012","unstructured":"Cawello W, Boekens H, Bonn R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet. 2012;37:241\u20138. https:\/\/doi.org\/10.1007\/s13318-012-0093-x.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1114_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"BK Beyreuther","year":"2007","unstructured":"Beyreuther BK, Freitag J, Heers C, Krebsf\u00e4nger N, Scharfenecker U, St\u00f6hr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13:21\u201342. https:\/\/doi.org\/10.1111\/j.1527-3458.2007.00001.x.","journal-title":"CNS Drug Rev"},{"key":"1114_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/FTD.0000000000000764","volume":"42","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Terada K, Araki Y, Fukushima Y, Imai K, Kagawa Y, et al. Therapeutic Monitoring of Lacosamide in Japanese Patients with Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range. Ther Drug Monit. 2020;42:754\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000000764.","journal-title":"Ther Drug Monit"},{"key":"1114_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.7150\/ijms.107660","volume":"22","author":"F Mao","year":"2025","unstructured":"Mao F, Chen S, Hu Y, Wang S, Chen M, Xu J, et al. Therapeutic Drug Monitoring for Lacosamide in Chinese Pediatric Patients with Epilepsy: Focus on Clinical Effectiveness, Tolerability and Drug Interactions. Int J Med Sci. 2025;22:1150\u20137. https:\/\/doi.org\/10.7150\/ijms.107660.","journal-title":"Int J Med Sci"},{"key":"1114_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/FTD.0000000000000599","volume":"41","author":"M Larsen Burns","year":"2019","unstructured":"Larsen Burns M, Nikanorova M, Baftiu A, Borg Rasmussen J, Johannessen SI, Johannessen Landmark C. Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway. Ther Drug Monit. 2019;41:340\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000599.","journal-title":"Ther Drug Monit"},{"key":"1114_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13318-019-00601-8","volume":"45","author":"L Schultz","year":"2020","unstructured":"Schultz L, Mahmoud SH. Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy? Eur J Drug Metab Pharmacokinet. 2020;45:315\u201349. https:\/\/doi.org\/10.1007\/s13318-019-00601-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1114_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492.","journal-title":"Pharmacopsychiatry"},{"key":"1114_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000336774","volume":"89","author":"SE Kim","year":"2012","unstructured":"Kim SE, Gu N, Kim BH, Fitchner A, Elshoff JP, Cawello W, et al. Pharmacokinetics of lacosamide in healthy Korean male volunteers. Pharmacology. 2012;89:172\u20138. https:\/\/doi.org\/10.1159\/000336774.","journal-title":"Pharmacology"},{"key":"1114_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/jcph.1840","volume":"61","author":"PB Lukka","year":"2021","unstructured":"Lukka PB, Woods M, Chhim R, Phelps SJ, Wheless JW, Meibohm B. Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age. J Clin Pharmacol. 2021;61:881\u20138. https:\/\/doi.org\/10.1002\/jcph.1840.","journal-title":"J Clin Pharmacol"},{"key":"1114_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/jcph.1340","volume":"59","author":"J Winkler","year":"2019","unstructured":"Winkler J, Schoemaker R, Stockis A. Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy. J Clin Pharmacol. 2019;59:541\u20137. https:\/\/doi.org\/10.1002\/jcph.1340.","journal-title":"J Clin Pharmacol"},{"key":"1114_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2018.10.011","volume":"149","author":"J Winkler","year":"2019","unstructured":"Winkler J, Schoemaker R, Stockis A. Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children. Epilepsy Res. 2019;149:13\u20136. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.10.011.","journal-title":"Epilepsy Res"},{"key":"1114_CR19","doi-asserted-by":"publisher","first-page":"109601","DOI":"10.1016\/j.yebeh.2023.109601","volume":"151","author":"J Wang","year":"2024","unstructured":"Wang J, Mei Y, Liang S, Li S, chan, Chen C, Nie G, et al. How to handle a missed or delayed dose of lacosamide in pediatric patients with epilepsy? a mode-informed individual dosing. Epilepsy Behav. 2024;151:109601. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109601.","journal-title":"Epilepsy Behav"},{"key":"1114_CR20","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1111\/bcp.14858","volume":"87","author":"SN Kalaria","year":"2021","unstructured":"Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02). Br J Clin Pharmacol. 2021;87:4375\u201385. https:\/\/doi.org\/10.1111\/bcp.14858.","journal-title":"Br J Clin Pharmacol"},{"key":"1114_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clinthera.2024.01.008","volume":"46","author":"X Zhu","year":"2024","unstructured":"Zhu X, Guo L, Zhang L, Xu Y. Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization. Clin Ther. 2024;46:258\u201366. https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.008.","journal-title":"Clin Ther"},{"key":"1114_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/FTD.0000000000001278","volume":"47","author":"Y Yamamoto","year":"2025","unstructured":"Yamamoto Y, Shiratani Y, Nishida T, Usui N, Kagawa Y, Takahashi Y, et al. Lacosamide Pharmacokinetics and Retention in Japanese Patients with Epilepsy: A Retrospective Study on the Influence of Age, Comedications, and Cytochrome P450 2C19 Polymorphism. Ther Drug Monit. 2025;47:407\u201312. https:\/\/doi.org\/10.1097\/FTD.0000000000001278.","journal-title":"Ther Drug Monit"},{"key":"1114_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","volume":"52","author":"W Cawello","year":"2013","unstructured":"Cawello W, Fuhr U, Hering U, Maatouk H, Halabi A. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clin Pharmacokinet. 2013;52:897\u2013906. https:\/\/doi.org\/10.1007\/s40262-013-0080-7.","journal-title":"Clin Pharmacokinet"},{"key":"1114_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/FTD.0000000000000538","volume":"40","author":"TW May","year":"2018","unstructured":"May TW, Helmer R, Bien CG, Brandt C. Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages. Ther Drug Monit. 2018;40:620\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000538.","journal-title":"Ther Drug Monit"},{"key":"1114_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit. 2018;40:526\u201348. https:\/\/doi.org\/10.1097\/FTD.0000000000000546.","journal-title":"Ther Drug Monit"},{"key":"1114_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40261-014-0177-2","volume":"34","author":"W Cawello","year":"2014","unstructured":"Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: Results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34:317\u201325. https:\/\/doi.org\/10.1007\/s40261-014-0177-2.","journal-title":"Clin Drug Investig"},{"key":"1114_CR27","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1177\/0091270011426875","volume":"52","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52:1739\u201348. https:\/\/doi.org\/10.1177\/0091270011426875.","journal-title":"J Clin Pharmacol"},{"key":"1114_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","volume":"36","author":"S Markoula","year":"2014","unstructured":"Markoula S, Teotonio R, Ratnaraj N, Duncan JS, Sander JW, Patsalos PN. Lacosamide serum concentrations in adult patients with epilepsy: The influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. 2014;36:494\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000051.","journal-title":"Ther Drug Monit"},{"key":"1114_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40261-015-0277-7","volume":"35","author":"C Schaefer","year":"2015","unstructured":"Schaefer C, Cawello W, Waitzinger J, Elshoff JP. Effect of Age and Sex on Lacosamide Pharmacokinetics in Healthy Adult Subjects and Adults with Focal Epilepsy. Clin Drug Investig. 2015;35:255\u201365. https:\/\/doi.org\/10.1007\/s40261-015-0277-7.","journal-title":"Clin Drug Investig"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01114-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:52:15Z","timestamp":1775739135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01114-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01114-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Program No: 20230374). The data in the hospital system are allowed to be used for research, and the data obtained remain anonymous.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Owing to the retrospective nature of the study and because participant data were anonymized, written informed consent was waived with the agreement of the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}